Coronary microvascular dysfunction (CMD) is associated with coronary artery diseases (CAD),
diabetic cardiomyopathy (DCM), ischemia with the non-obstructive coronary artery (INOCA), and
HFpEF (heart failure with preserved ejection fraction). Patients with diabetes exhibit coronary
endothelial dysfunction, which is characterized by impaired acetylcholine-induced endothelial-
dependent relaxation. Impaired endothelium-dependent vasodilation (EDD) decreases coronary
blood flow and myocardium perfusion, leading to myocardial ischemia even without an obstructive
coronary artery. However, the underlying mechanism of impaired coronary endothelial dilation in
DCM is not fully understood. Our preliminary study finds that NO is the mediator of endothelium-
dependent dilation (EDD) in small coronary arteries in healthy mice. However, in diabetic mice,
we observe that hydrogen peroxide (H2O2) is the principal endothelial-dependent vasodilator.
Such a unique preclinical diabetic model recapitulates a clinical observation of NO to H2O2 in CAD
patients.
Moreover, we find a deficiency of miR-21 that restores the NO-dependent coronary vasodilation.
This application will address the underlying mechanism of how miR-21 regulates the NO to H2O2
switches in diabetes and the pathological consequence of the switch in DCM. We hypothesize
that restoring “normal” coronary microvascular function (restoring endothelial dilation) by
modulating miR-21can ameliorate diabetic cardiomyopathy (which is thought to be a disease
related to impaired coronary microvascular function). We will test our hypothesis by an
interdisciplinary approach encompassing a range of methods and disciplines from molecular and
cell analyses, vascular biology to physiology and pathophysiology, engendering the study of a
novel mechanism of coronary microvascular dysfunction, such as tissue-specific knockouts and
lineage tracing with 3D fluorescent imaging, measurement of vasodilation and myocardial blood
flow in vivo by contrast echocardiography and cardiac function by echocardiography along with
RNA-seq, sc RNA-seq, etc. Completing this project may lead to a new strategy to treat
microvascular dysfunction and diabetic cardiomyopathy and improve the cardiovascular
prognosis of diabetes.